Receive The Newest Study Notifications

Concert Pharmaceuticals Completes Enrollment in Second Open Label Trial of CTP-543 to Evaluate Once-Daily vs. Twice-Daily Dosing in Patients with Alopecia Areata

by Lance Smith | Sep 17, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia areata. Topline data from...

Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy

by Lance Smith | Sep 17, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083 in patients with facioscapulohumeral muscular...

Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

by Lance Smith | Sep 17, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the treatment of the last patient in the primary cohort of the Phase IIb HbA1c trial evaluating...

Soliton Completes Trial Enrollment and Conducts Initial Site Training to Start Keloid Trial

by Lance Smith | Sep 17, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Soliton, Inc., (SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today...

REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor

by Lance Smith | Sep 17, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Combination Inhibits Upstream and Downstream Targets in Oncogenic RAS Signaling Pathway, Offering Potential for Synergistic Anti-Tumor Benefit REVOLUTION Medicines, Inc., a clinical-stage oncology company focused on developing novel targeted therapies to inhibit...

First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence

by Lance Smith | Sep 16, 2019 | Study Scavenger Clinical Trial Recruitment Platform

CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that Hannover Medical...